The Preemptive Analgesic Efficacy of Nefopam
- Registration Number
- NCT02561468
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Nefopam is administered as a preemptive analgesic drug to the patient undergoing breast cancer surgery. It will be evaluated whether postoperative acute and chronic pain can be reduced.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 94
Inclusion Criteria
- Patients diagnosed with breast cancer
- Lumpectomy with axillary lymph node dissection or Lumpectomy with sentinel lymph node biopsy
- American Society of Anesthesiologists physical status I or II
Exclusion Criteria
- Refusal
- Seizure
- Cardiac disease
- Monoamine oxidase inhibitor user
- Urologic disease
- Glucoma
- Preoperative analgesic drug medication
- Pregnancy
- Recurred breast cancer patient
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Nefopam Nefopam 20 mg nefopam in 100 ml normal saline is infused before starting operation. Control Saline 100 ml normal saline is infused before starting operation.
- Primary Outcome Measures
Name Time Method The change of pain numerical rating score from postoperative 30 min until postoperative 3 month Postoperative 30 min, postoperative 1 day, postoperative 1 week, postoperative 3 month
- Secondary Outcome Measures
Name Time Method The dose of ketorolac administered to the patient. postoperative 1 day
Trial Locations
- Locations (1)
Seoul National University Bundang Hospital
🇰🇷Seongnam, Gyeonggi, Korea, Republic of